Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Artia Global Partners LP

Artia Global Partners LP increased its stake in Insmed Incorporated (NASDAQ:INSM) by 217.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 167,939 shares of the biopharmaceutical company’s stock after acquiring an additional 115,000 shares during the quarter. Insmed makes up 4.1% of Artia Global Partners LP’s holdings, making the stock its 11th largest holding. Artia Global Partners LP’s holdings in Insmed were worth $11,595,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed in the 4th quarter valued at $47,000. Smartleaf Asset Management LLC boosted its holdings in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the fourth quarter worth $86,000.

Insmed Stock Performance

INSM opened at $69.69 on Friday. The stock has a market cap of $12.67 billion, a PE ratio of -12.47 and a beta of 1.07. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The stock’s 50 day simple moving average is $74.38 and its 200-day simple moving average is $73.56. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on INSM. JPMorgan Chase & Co. upped their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Bank of America boosted their price objective on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Wells Fargo & Company lifted their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Insider Activity

In other news, CEO William Lewis sold 6,830 shares of the business’s stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company’s stock, valued at $16,412,107.84. The trade was a 2.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares of the company’s stock, valued at $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 471,797 shares of company stock worth $37,621,239. Company insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.